Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Aug;26(2):155–159. doi: 10.1128/aac.26.2.155

Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

E de Clercq
PMCID: PMC284110  PMID: 6486759

Abstract

(E)-5-(2-Bromovinyl)-2'-deoxyuridine (bromovinyldeoxyuridine) was found to suppress the development of herpetic skin lesions and the paralysis and mortality associated therewith in hairless mice inoculated intracutaneously with herpes simplex virus type 1. This protective effect was achieved with bromovinyldeoxyuridine applied topically at 1, 3, or 10% in either dimethylsulfoxide (DMSO), Beeler base, Tween-glycerol-water, 5% Azone (1-dodecylazacycloheptan-2-one) in water, or 5% Azone in DMSO. The optimal vehicle was 5% Azone in DMSO, in which bromovinyldeoxyuridine was effective even at a concentration as low as 0.3%. In its protective activity against cutaneous herpes simplex virus type 1 infection in hairless mice, bromovinyldeoxyuridine was clearly superior to other established antiherpes compounds such as 5-iodo-2'-deoxyuridine, 5-ethyl-2'-deoxyuridine, arabinosyl thymine, and arabinosyl (E)-5-(2-bromovinyl) uracil when formulated at 10% in DMSO or Azone-DMSO. However, no activity was noted with any of these drug formulations against cutaneous herpes simplex virus type 2 infection. In contrast, acycloguanosine (acyclovir) proved quite effective in the topical treatment of cutaneous herpes simplex virus type 2 infection when used at 10% in DMSO or at 5% in propylene glycol.

Full text

PDF
157

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alenius S., Berg M., Broberg F., Eklind K., Lindborg B., Oberg B. Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. J Infect Dis. 1982 Apr;145(4):569–573. doi: 10.1093/infdis/145.4.569. [DOI] [PubMed] [Google Scholar]
  2. Alenius S., Dinter Z., Oberg B. Therapeutic effect of trisodium phosphonoformate on cutaneous herpesvirus infection in guinea pigs. Antimicrob Agents Chemother. 1978 Sep;14(3):408–413. doi: 10.1128/aac.14.3.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Alenius S., Oberg B. Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs. Arch Virol. 1978;58(4):277–288. doi: 10.1007/BF01317820. [DOI] [PubMed] [Google Scholar]
  4. Collins P., Oliver N. M. Acyclovir treatment of cutaneous herpes in guinea pigs and herpes encephalitis in mice. Am J Med. 1982 Jul 20;73(1A):96–99. doi: 10.1016/0002-9343(82)90072-9. [DOI] [PubMed] [Google Scholar]
  5. De Clercq E. Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob Agents Chemother. 1982 Apr;21(4):661–663. doi: 10.1128/aac.21.4.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  7. De Clercq E., Zhen-Xi Zhang Differential effects of E-5-(2-bromovinyl)-2'-deoxyuridine on infections with herpes simplex virus type 1 and type 2 in hairless mice. J Infect Dis. 1982 Jan;145(1):130–130. doi: 10.1093/infdis/145.1.130. [DOI] [PubMed] [Google Scholar]
  8. Descamps J., De Clercq E., Barr P. J., Jones A. S., Walker R. T., Torrence P. F., Shugar D. Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice. Antimicrob Agents Chemother. 1979 Nov;16(5):680–682. doi: 10.1128/aac.16.5.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fiddian A. P., Yeo J. M., Stubbings R., Dean D. Successful treatment of herpes labialis with topical acyclovir. Br Med J (Clin Res Ed) 1983 May 28;286(6379):1699–1701. doi: 10.1136/bmj.286.6379.1699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Klein R. J., DeStefano E., Brady E., Friedman-Kien A. E. Latent infections of sensory ganglia as influenced by phosphonoformate treatment of herpes simplex virus-induced skin infections in hairless mice. Antimicrob Agents Chemother. 1979 Sep;16(3):266–270. doi: 10.1128/aac.16.3.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Klein R. J., Friedman-Kien A. E., DeStefano E. Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob Agents Chemother. 1979 May;15(5):723–729. doi: 10.1128/aac.15.5.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klein R. J., Friedman-Kien A. E., Fondak A. A., Buimovici-Klein E. Immune response and latent infection after topical treatment of herpes simplex virus infection in hairless mice. Infect Immun. 1977 Jun;16(3):842–848. doi: 10.1128/iai.16.3.842-848.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Klein R. J., Friedman-Kien A. E. Latent herpes simplex virus infections in sensory ganglia of mice after topical treatment with adenine arabinoside and adenine arabinoside monophosphate. Antimicrob Agents Chemother. 1977 Nov;12(5):577–581. doi: 10.1128/aac.12.5.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Klein R. J., Friedman-Kien A. E., Yellin P. B. Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment. Infect Immun. 1978 Apr;20(1):130–135. doi: 10.1128/iai.20.1.130-135.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pancic F., Steinberg B. A., Diana G. D., Carabateas P. M., Gorman W. G., Came P. E. Antiviral activity of Win 41258-3, a pyrazole compound, against herpes simplex virus in mouse genital infection and in guinea pig skin infection. Antimicrob Agents Chemother. 1981 Mar;19(3):470–476. doi: 10.1128/aac.19.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Spruance S. L., Schnipper L. E., Overall J. C., Jr, Kern E. R., Wester B., Modlin J., Wenerstrom G., Burton C., Arndt K. A., Chiu G. L. Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. J Infect Dis. 1982 Jul;146(1):85–90. doi: 10.1093/infdis/146.1.85. [DOI] [PubMed] [Google Scholar]
  17. Stoughton R. B. Enhanced percutaneous penetration with 1-dodecylazacycloheptan-2-one. Arch Dermatol. 1982 Jul;118(7):474–477. [PubMed] [Google Scholar]
  18. Teh C. Z., Sacks S. L. Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2. Antimicrob Agents Chemother. 1983 May;23(5):637–640. doi: 10.1128/aac.23.5.637. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES